26
Views
4
CrossRef citations to date
0
Altmetric
Original Article

Prospective study of methotrexate treatment for rheumatoid arthritis treated legitimately according to the government recommended 8 mg/week dose

, , , , , , , , , , , , , , & show all
Pages 637-642 | Received 17 Mar 2009, Accepted 22 Jun 2009, Published online: 02 Jan 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Yasuo Suzuki, Naonobu Sugiyama, Yuri Fukuma, Noriko Sugiyama & Takeshi Kokubo. (2020) Safety and effectiveness of high-dose methotrexate (over 8 mg/week) in 2838 Japanese patients with rheumatoid arthritis: a postmarketing surveillance report. Modern Rheumatology 30:1, pages 24-35.
Read now
Yohei Seto, Eiichi Tanaka, Eisuke Inoue, Ayako Nakajima, Atsuo Taniguchi, Shigeki Momohara & Hisashi Yamanaka. (2011) Studies of the efficacy and safety of methotrexate at dosages over 8 mg/week using the IORRA cohort database. Modern Rheumatology 21:6, pages 579-593.
Read now

Articles from other publishers (2)

Chikashi Terao, Noriyuki Yamakawa, Koichiro Yano, Iris M. Markusse, Katsunori Ikari, Shinji Yoshida, Moritoshi Furu, Motomu Hashimoto, Hiromu Ito, Takao Fujii, Koichiro Ohmura, Kosaku Murakami, Meiko Takahashi, Masahide Hamaguchi, Yasuharu Tabara, Atsuo Taniguchi, Shigeki Momohara, Soumya Raychaudhuri, Cornelia F. Allaart, Hisashi Yamanaka, Tsuneyo Mimori & Fumihiko Matsuda. (2015) Rheumatoid Factor Is Associated With the Distribution of Hand Joint Destruction in Rheumatoid Arthritis. Arthritis & Rheumatology 67:12, pages 3113-3123.
Crossref
Martin Lopez, Daniel Meier, Andreas Müller, Paul Franken, Jun Fujita & Adriano Fontana. (2014) Tumor Necrosis Factor and Transforming Growth Factor β Regulate Clock Genes by Controlling the Expression of the Cold Inducible RNA-binding Protein (CIRBP). Journal of Biological Chemistry 289:5, pages 2736-2744.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.